| Income Statement | 2025-09-30 | 2025-03-31 | 2024-09-30 | |
|---|---|---|---|---|
| Sales, net | 12,689 | 13,947 | 13,617 | |
| Cost of sales | 11,670 | 12,396 | 12,246 | |
| Gross profit | 1,019 | 1,551 | 1,371 | |
| Selling and administrative expenses | 856 | 812 | 881 | |
| Operating income | 163 | 739 | 490 | |
| Other income (expense), net | - | 34 | - | |
| Interest income, net | -33 | -5 | -14 | |
| Other income (expense), net | - | 39 | - | |
| Income before income taxes | 196 | 778 | 504 | |
| Income tax expense, net | 73 | 167 | 245 | |
| Net income | 123 | 611 | 259 | |
| Basic net income per common share (in dollars per share) | 0 | 0.02 | 0.01 | |
| Diluted net income per common share (in dollars per share) | 0 | 0.02 | 0.01 | |
| Us-gaap_weightedaveragenumberofdilutedsharesoutstanding | 31,421,338 | 31,514,591 | 30,649,977 | |
| Weighted average common shares outstanding - basic (in shares) | 31,059,610 | 30,300,720 | 30,099,610 | |
INTEGRATED BIOPHARMA INC (INBP)
INTEGRATED BIOPHARMA INC (INBP)